Compounders Research Compare

ProKidney Corp.(PROK)

Biotechnology · Winston-Salem, NC

$1.59+0.01 (+0.63%)

Delayed quote: Oct 6, 2026, 2:05 PM EDT

About ProKidney Corp.

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Winston-Salem, NC

231 employees

www.prokidney.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bruce Culleton

View full financials

ProKidney (PROK) Price/FCF Ratio: History & Chart | TGMCharts

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T18:09:12.914Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:09:12.914Z.

Quote observation: 2026-10-06T18:05:22.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 534,643,666
TTM free cash flow · period ending 2026-06-30: -159,734,000

FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PROK Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

PROK Competitors' Price/FCF Ratio

ProKidney Corp.

Current

Market Cap

$534.64M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$535.32M

Price/FCF Ratio

30.58

TTM Avg

34.94

3Y Avg

46.00

5Y Avg

46.00

Nuvectis Pharma, Inc.

Market Cap

$533.65M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$531.89M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BlossomHill Therapeutics, Inc.

Market Cap

$531.89M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Shattuck Labs, Inc.

Market Cap

$539.20M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclaris Therapeutics, Inc.

Market Cap

$528.39M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$540.88M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$520.90M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$520.22M

Price/FCF Ratio

N/A

TTM Avg

0.26

3Y Avg

0.26

5Y Avg

0.26

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
ProKidney Corp. (PROK)	$534.64M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$535.32M	30.58	34.94	46.00	46.00
Nuvectis Pharma, Inc. (NVCT)vs ›	$533.65M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$531.89M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$531.89M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$539.20M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$528.39M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$540.88M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$520.90M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$520.22M	N/A	0.26	0.26	0.26

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics